Study To Evaluate The Efficacy Of Tofacitinib In Patients With SJS/TEN

Launched by CHANG GUNG MEMORIAL HOSPITAL · Jun 19, 2024

Keywords

ClinConnect Summary

This clinical trial is studying the effects of a medication called tofacitinib on patients with Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), which are serious skin reactions that can cause painful blisters and skin loss. The main goal of the study is to see how long it takes for the skin to heal completely after treatment. They will also look at other important factors, like how many people recover, how long they stay in the hospital, and any side effects that may occur during the study.

To participate in this trial, individuals must be between 20 and 90 years old and have been diagnosed with SJS or TEN by two dermatologists. They need to be willing to sign a consent form to join. However, people who are pregnant, breastfeeding, have certain serious infections, or specific heart conditions are not eligible to participate. If someone joins the trial, they can expect to receive the medication and be closely monitored for their recovery and any potential side effects throughout the study.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Willing to sign inform consent form
• • 2. Subject has been diagnosed with Stevens-Johnson syndrome or toxic epidermal necrolysis by at least two dermatologists.
• • 3. Male or female aged over 20 years old and under 90 years old.
• Exclusion Criteria:
• • 1. Subject or legally authorized representative is not willing to provide informed consent.
• • 2. Women who are pregnant or breastfeeding
• • 3. Subject has an active, untreated, or serious infectious disease that is ineffective in treatment, such as sepsis.
• • 4. Subject suffers from severe life-threatening cardiac arrhythmia, such as ventricular tachycardia, have had myocardial infarction (myocardial infarction), severe hypertension that has not responded to treatment within the past week, or other cardiologist diagnosed severe cardiovascular disease
• • 5. Subject has active viral hepatitis
• • 6. Subject has active tuberculosis
• • 7. Subject received live vaccination during the illness